Stockholders Approve Equity Incentive Plan with Over 10% Potential Dilution
PSTV sits 78% above its 52-week low of $2.9.
Summary
PLUS THERAPEUTICS, INC. stockholders approved an amended equity incentive plan, which could lead to over 10% dilution, alongside the re-election of directors and other routine proposals at its Annual Meeting.
Key Events · Corporate Governance and Compliance · PSTV
-
Equity Incentive Plan Approved
Stockholders approved the Sixth Amendment and Restatement of the 2020 Stock Incentive Plan. This plan, previously proposed in a March 31, 2026 DEF 14A filing, authorizes the issuance of an additional 740,000 shares (post-reverse split) for compensation. If all authorized shares were issued, dilution would be approximately 10.78%.
-
Directors Re-elected
Six directors — Howard Clowes, An van Es-Johansson, M.D., Richard J. Hawkins, Marc H. Hedrick, M.D., Ronald A. Andrews, and Kyle Guse, Esq., MBA, CPA — were re-elected to the Board of Directors for terms expiring in 2027.
-
Auditor Ratified
The appointment of CBIZ CPAs, P.C. as the independent registered public accounting firm for the 2026 fiscal year was ratified by stockholders.
-
Executive Compensation Approved
Stockholders approved, on an advisory basis, the compensation of the company's named executive officers.
Analysis · PSTV · Industrial Applications And Services
Stockholders approved the Sixth Amendment and Restatement of the 2020 Stock Incentive Plan. This approval authorizes the company to issue an additional 740,000 shares (post-reverse split) for equity compensation. If all these shares were issued, it would result in a potential dilution of approximately 10.78% for existing shareholders. This is a significant amount for a company that recently reported substantial doubt about its ability to continue as a going concern, as noted in its March 12, 2026 10-K filing. While common for employee incentives, the magnitude of potential dilution is notable given the company's financial context.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.4% of the 1070 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PSTV was trading at $5.16 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $36M. The 52-week trading range was $2.90 to $23.43. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.